| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that a Company-sponsored experiment on the Company's SonoRepro™ product was recently conducted by Dr. Akinobu Miyata, Director of Miyata Medical Clinic, in collaboration with the Japan Clinical Trial Association (JACTA).
The study, aimed at determining the effects on the scalp and hair when using SonoRepro™ with scalp lotion for 12 weeks, consisted of adult men and women under 49 years old who were concerned about thinning hair. The goal of the study was to utilize a test group and control group to determine whether results were significant.
As part of the study, scalp lotion was applied to the top of the head, and ultrasonic waves were irradiated to the scalp by SonoRepro™ to cover the center of the application area. SonoRepro™'s non-contact vibrotactile stimulation is a technology that irritates the skin without physically touching it, using ultrasonic waves transmitted through the air.
In comparing the results of the test group with the control group, the outcome revealed that the study participants who received treatment via SonoRepro™ showed a meaningful improvement in hair diameter, head condition, and scalp water content.
"The recent study evidenced the efficacy of our technology across both genders and different age groups," said Pixie Dust Technologies, Inc. CRO Takayuki Hoshi. "Moving forward, we intend to further explore the potential of our wave control technology in the healthcare sector."
Posted In: PXDT
